Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td align="left">Trade name </td><td align="center">Company </td><td align="center">Authorised by</td><td align="center">Cell type </td><td align="left">Indication </td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td align="left">Hearticellgram<sup>*</sup></td><td align="center">FCB PharmiCell</td><td align="center">KFDA (2011)</td><td align="center">Autologous BM-derived MSCs </td><td align="left">Treatment for postacute myocardial infarction </td></tr><tr><td align="left">Cartistem<sup>*</sup></td><td align="center">Medipost </td><td align="center">KFDA (2012)</td><td align="center">Allogeneic hUCB-MSCs</td><td align="left">Treatment of traumatic and degenerative osteoarthritis </td></tr><tr><td align="left">Prochymal<sup>*</sup></td><td align="center">Osiris Therapeutics Inc. </td><td align="center">Health Canada (2012) <br/>New Zealand (2012) </td><td align="center">Allogeneic BM-MSCs</td><td align="left">Treatment of acute GvHD children who are unresponsive to steroids</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>MSCs: mesenchymal stem cells; BM: bone marrow; hUCB: human umbilical cord blood; GvHD: graft-versus-host disease; KFDA: Korean Food and Drug Administration.<br/><sup>*</sup>SCTMP: somatic cell therapy medicinal product.<br/></td></tr></table>

MSC cell-based therapies with a valid marketing authorisation.

Stem Cells International

tab3

Table 3

Table 3: Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells 